Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue

Pacific Biosciences (PACB) reported Q3 2026 revenue growth of 6% YoY to $40.6M, with consumables revenue down 2% YoY. Non-GAAP gross margin fell to 36% from 42% due to higher costs. Americas and Asia Pacific revenues declined, while EMEA grew 30%. Cash burn was $32.8M, with Q4 expected to decrease. The company narrowed full-year revenue guidance to $155M-$160M and expects cash flow breakeven in 2028.

Original reporting
Published Nov 5, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue — source image
Decision brief

The 30-second read

$PACBBearishMed
01

Why it matters

The earnings release provides fresh guidance and margin data that were not previously public, making it a primary source of market‑moving information.

02

Market read

Earnings miss and lowered guidance likely trigger short‑term sell pressure, while long‑term product developments could mitigate downside.

03

What to watch

The high‑throughput platform slated for 2027 could unlock larger contracts, and the clinical segment now exceeds 20% of revenue.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Pacific Biosciences (PACB) reported its Q3 2026 results, highlighting modest revenue growth, margin compression, and a revised full‑year outlook.

Company-level read

Ticker impact

$PACBBearishHigh confidence
Context

Q3 2026 earnings released with revenue $40.6M (+6% YoY) and non‑GAAP net loss $32.8M, margin down to 36%, and lowered full‑year guidance.

Expected impact

likely downside as investors price in weaker margins and reduced guidance

Evidence & confidence

Guidance narrowed, margins fell, and cash burn remains high, all negative catalysts for a small‑cap biotech.

Market effects

Signals continued pressure on long‑read sequencing vendors as consumable transition slows revenue.

Americas revenue weakness highlights funding uncertainty for academic research in the US.

May affect investor sentiment toward niche genomics equipment makers worldwide.

Counterpoint

If SparkNext adoption accelerates, long‑term cash burn could improve, offering a buying opportunity at depressed levels.

Key entities

  • Mark Van Oene

    Provided commentary on SparkNext adoption and product roadmap.

  • Bill Meyer

    Presented financial results and guidance.

Related articles

$PACBHighAI 8/10

What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call

Pacific Biosciences (PACB) reported Q3 earnings, with Revio consumables pull-through at $204,000 per system. Instrument revenue rose to $13.2M, with 15 Revio and 35 Vega systems sold. Clinical business grew over 20% YoY, now exceeding 20% of total business. Non-GAAP net loss narrowed to $32.8M, with cash at $199.4M. The company maintained its 2026 outlook and expects cash flow breakeven in 2028.

$PACBMed

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB): PacBio Announces Third Quarter 2026 Financial Results

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PacBio Announces Third Quarter 2026 Financial Results MENLO PARK, Calif., November 4, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026. Recent Business Highlights • Delivered total revenue of $40

$PACBMed

Why PacBio (PACB) Stock Is Trading Up Today

Pacific Biosciences of California (PACB) shares rose 15% to $2.88 after EpiSign and Geneyx announced a partnership using PacBio's HiFi sequencing for rare disease analysis. The stock is up 56.5% year-to-date, reaching a 52-week high. PacBio's shares are volatile, with 87 moves over 5% in the past year.

$PACBMed

Why Is PacBio (PACB) Stock Soaring Today

Pacific Biosciences (PACB) stock rose 29.7% after EpiSign launched EpiSign METRIC 5-base, a software for DNA methylation data analysis on PacBio's HiFi sequencing platform. The tool also supports Illumina and Oxford Nanopore platforms. PacBio's shares have seen high volatility, with an 86% move over the past year. The stock is up 30.4% YTD but still 9.9% below its 52-week high.